Tumors Clinical Trial - Comparing Magnetic Resonance Imaging/Spectroscopy

Status Terminated

Clinical Trial Summary

Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are diagnostic tests that allow researchers to look at different chemical properties of tissue. Magnetic resonance imaging and spectroscopy studies can be used to gather or evaluate information about various aspects of patient s bodies or to monitor changes in the biochemistry and physiology of patient s bodies.

Unlike other diagnostic techniques (CT scan and PET scan) MRI and MRS do not use ionizing radiation. Some studies have shown that MRI is more effective at distinguishing normal parts of the anatomy from abnormal anatomy, especially in the brain. MRI has become the diagnostic test of choice for evaluating patient with multiple sclerosis.

The purpose of this study is to evaluate normal volunteers and patients with a variety of diseases with magnetic resonance imaging. Researchers will attempt different magnetic resonance imaging methods and techniques as well as different levels of magnetic strength.

Clinical Trial Description

Background:

MRI is a constantly evolving imaging modality. Pulse sequences are often modified to improve their performance. However, many of these changes have not yet been approved by the FDA and therefore, are not considered standard of care. Some of these sequences require the use of new types of imaging coils, which are also investigational.

Objectives:

The major purpose of this protocol is to inform patients undergoing MR scans in the Clinical Center that they be scanned with MRI sequences and/or coils which may or may not be FDA approved and to get the patient s consent for this. This is not a formal research study since specific disease entities and specific pulse sequences are not studied in a systematic way. Rather, the purpose is to give NIH patients access to gradual improvements in MR technology that would otherwise not be available to them.

Eligibility:

All patients who, by virtue of the NIH protocol in which they are enrolled, qualify for MRI will be eligible for participation in this protocol.

Design:

Up to 99,999 participants will be enrolled in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001219
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Terminated
Phase
Start date	June 18, 1987
Completion date	June 3, 2020

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT01562626` - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors	Phase 1/Phase 2
Completed	`NCT00435669` - A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)	Phase 1
Completed	`NCT00400023` - A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors	Phase 1
Completed	`NCT00372437` - A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine	Phase 1/Phase 2
Completed	`NCT00375245` - Rapamycin With Grapefruit Juice for Advanced Malignancies	Phase 1
Completed	`NCT00395434` - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00410696` - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy	Phase 2
Recruiting	`NCT00553033` - Laparoscopic Liver Resection	N/A
Completed	`NCT00248404` - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)	Phase 1/Phase 2
Completed	`NCT00207103` - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT00222443` - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy	Phase 1
Terminated	`NCT03251924` - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05103969` - Cohort of Tumors With POLE/D1 Mutation
Completed	`NCT00446446` - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)	Phase 2
Completed	`NCT02275910` - Phase 1 Study of E7090 in Subjects With Solid Tumor	Phase 1
Terminated	`NCT02271516` - to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage	Phase 1
Completed	`NCT01448759` - Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel	N/A
Terminated	`NCT01081808` - Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors	Phase 1
Completed	`NCT00398814` - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers	Phase 1
Completed	`NCT00389480` - Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparing Magnetic Resonance Imaging/Spectroscopy Techniques

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms